MichaelJamesHallMDMSc(Zir)

PubMed

• Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
  Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, Chistyakov V, Höhler T, Kim J, Hofheinz R, Ackland SP, Swinson D, Kopp M, Udovitsa D, Hall M, Ive...> ;Ann. Oncol.. 2016-07-01
• A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: ...
  Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G, Lamont A, Hindley A, Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley L, Hall M, Vasey P, Ka...> ;Ann. Oncol.. 2013-03-01
• Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
  Okines AFC, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson T...> ;Ann. Oncol.. 2013-03-01
• Mechanistic insight into the formation of tetraarylazadipyrromethenes.
  Grossi M, Palma A, McDonnell SO, Hall MJ, Rai DK, Muldoon J, O'Shea DF> ;J. Org. Chem.. 2012-10-19
• Significance of pathologic response to preoperative therapy in pancreatic cancer.
  Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP> ;Ann. Surg. Oncol.. 2011-12-01
• Utility of Noninvasive Aneurysm Sac Pressure Measurement during and after Endovascular Abdominal Aortic Aneurysm Repair.
  Hall, M.J., Duprat, G.I.> ;J Vasc Interv Radiol. 2011 Jul
• Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
  Hall, M.J., Reid, J.E., Wenstrup, R.J.> ;Cancer Prev Res (Phila). 2010 Dec
• Defining venous involvement in borderline resectable pancreatic cancer.
  Chun, Y.S., Milestone, B.N., Watson, J.C., Cohen, S.J., Burtness, B., Engstrom, P.F., Haluszka, O., Tokar, J.L., Hall, M.J., Denlinger, C.S., Astsaturov, I., Hoffman, ...> ;Ann Surg Oncol. 2010 Nov
• Testicular ischemia following endovascular infrarenal abdominal aortic aneurysm repair: a rare complication.
  Hall, M.J., Duprat, G.I., Poulin, T.L.> ;J Vasc Interv Radiol. 2010 Oct
• Thermal 1,3-trityl migrations in Diels-Alder domino reactions of 1-trityl-4-vinyl-1H-imidazoles.
  Cotterill, L.J., Harrington, R.W., Clegg, W., Hall, M.J.> ;J Org Chem. 2010 Jul 2
• Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients--will the ends justify the means?
  Hall, M.J.> ;J Natl Compr Canc Netw. 2010 May
• Clinical trials that explicitly exclude gay and lesbian patients.
  Egleston, B.L., Dunbrack, R.L., Hall, M.J.> ;N Engl J Med. 2010 Mar 18
• Dispersal of biofilms by secreted, matrix degrading, bacterial DNase.
  Nijland, R., Hall, M.J., Burgess, J.G.> ;PLoS One. 2010
• Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
  Forman, A.D., Hall, M.J.> ;Breast J. 2009-09-01
• Risk of colorectal neoplasia associated with the adenomatous polyposis coli E1317Q variant.
  Hall, M. J.,Liberman, E.,Dulkart, O.,Galazan, L.,Sagiv, E.,Shmueli, E.,Kazanov, D.,Hallak, A.,Moshkowitz, M.,Figer, A.,Kraus, S.,Inbar, M.,Neugut, A. I.,Arber, N.> ;Ann. Oncol.. 2009 May 29
• Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
  Gold, H.T., Hall, M.J., Blinder, V., Schackman, B.R.> ;Cancer. 2009-09-01
• BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
  Hall, M.J., Reid, J.E., Burbidge, L.A., Pruss, D., Deffenbaugh, A.M., Frye, C., Wenstrup, R.J., Ward, B.E., Scholl, T.A., Noll, W.W.> ;Cancer. 2009 May 15
• A convergent approach toward the C1-C11 subunit of phoslactomycins and formal synthesis of phoslactomycin B.
  Druais, V., Hall, M.J., Corsi, C., Wendeborn, S.V., Meyer, C., Cossy, J.> ;Org Lett. 2009-02-19
• Genetic services have value beyond BRCA1/2 testing.
  Hall, M.J.> ;Cancer Epidemiol Biomarkers Prev. 2009-02-01
• B,O-chelated azadipyrromethenes as near-IR probes.
  Loudet, A., Bandichhor, R., Burgess, K., Palma, A., McDonnell, S.O., Hall, M.J., O'Shea, D.F.> ;Org Lett. 2008-11-06
• Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment.
  Hall, M.J., Dignam, J.J., Olopade, O.I.> ;J Genet Couns. 2008 Aug
• Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer.
  Hershman, D., Hall, M.J., Wang, X., Jacobson, J.S., McBride, R., Grann, V.R., Neugut, A.I.> ;Cancer. 2006 Dec 1
• Disparities in genetic testing: thinking outside the BRCA box.
  Hall, M.J., Olopade, O.I.> ;J Clin Oncol. 2006 May 10
• Review: only women with specific family histories should be referred for counseling or evaluation for BRCA breast and ovarian cancer susceptibility testing.
  Hall, M.J., Neugut, A.I.> ;ACP J Club. 2006-03-01
• Supramolecular photonic therapeutic agents.
  McDonnell, S.O., Hall, M.J., Allen, L.T., Byrne, A., Gallagher, W.M., O'Shea, D.F.> ;J Am Chem Soc. 2005 Nov 30
• Join now to see all